ABUS - Latest News

Arbutus Biopharma Corporation (ABUS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $848.8M. Trailing twelve-month P/E ratio is 5.20. Beta to the broader market is 0.62.

The article list below shows the most recent ABUS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ABUS Headlines

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

globenewswire.com - May 13, 2026

Q1 total revenue of $179.

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

globenewswire.com - Apr 15, 2026

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa. , April 15, 2026 (GLOBE NEWS

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

globenewswire.com - Mar 23, 2026

Strong financial position with cash, cash equivalents and marketable securities of $91.

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

wsj.com - Mar 3, 2026

The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

accessnewswire.com - Mar 3, 2026

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Secti

How News Affects ABUS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ABUS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ABUS news questions

What is the latest ABUS news headline?

The most recent ABUS headline (May 13, 2026) is "Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ABUS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ABUS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ABUS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.